Michael Gorgievski

Michael Gorgievski has over 19 years of work experience in the biotechnology industry. Michael began their career as a Manufacturing Technician at Genzyme in 2001. Michael then moved to Charles River Laboratories as a Research Technician in 2002. In 2005, they became a Biomedical Development Associate IV at Sanofi-Pasteur (Acambis campus Cambridge). In 2010, they assumed the role of Animal Facility Manager/Sr. Research Associate at Anchor Therapeutics, where they designed and conducted in vivo studies and assisted with OGTT and Lipolysis studies for the Metabolic Disease Portfolio. In 2013, they held two positions simultaneously as a Research Associate at Moderna Therapeutics and a Senior Research Associate at Alkermes. From 2014-2017, they worked at PerkinElmer, Inc. as an In Vivo Imaging Research Associate, playing a significant role in animal study IACUC committee including protocol review, update, monitor, and report. Michael also successfully designed and performed in vivo contracted projects including oncology studies and infectious studies, biodistribution studies, and R&D projects for clinical imaging agent development. In 2018, they joined Sigilon Therapeutics, Inc. as a Senior Associate Scientist. Most recently, in 2021, they began working at Myeloid Therapeutics as an In-Vivo, Translational Sciences.

Michael Gorgievski attended Worcester Polytechnic Institute, where they studied chemistry, organic chemistry, biochemistry, and cell biology.